August 12, 2018 – Findings from a retrospective case-control study were published online August 8, 2018, in JAMA Dermatology indicate that the use of certain dipeptidyl peptidase 4 (DPP-4) inhibitor drugs are associated with a small but significantly elevated risk for developing bullous …

Risk of Bullous Pemphigoid with Type 2 Diabetes Drugs Read more »

Tagged with: , , , , , , , , , , , , ,

May 06, 2018 – In April 2016 the American Food and Drug Administration (FDA) took regulatory action by mandating label changes with new warnings about an increased risk of heart failure for  new diabetes medicines in the dipeptidyl peptidase-4 (DPP-4) …

Heart attacks and stroke: The risk of DPP-4 anti-diabetes drugs Read more »

Tagged with: , , , , , , , , , , , , , , , ,

October 15, 2017 – According to the quarterly safety report April – June 2017 by the American Food & Drug Administration (FDA), originating from the  FDA Adverse Event Reporting System (FAERS), the class of diabetes drugs referred to as dipeptidyl peptidase-4 …

Diabetes: Is rhabdomyolysis associated with DPP-IV inhibitors? Read more »

Tagged with: , , , , , , , , , , , , , , , , , , , , , , , , ,

October 14, 2009 – On October 5, 2009, drug maker Bristol-Myers Squibb Co. announced that its new diabetes drug, Saxagliptin [Onglyza], has been approved for sale in the European Union’s (EU) 27 countries. Saxagliptin [Onglyza] is the first diabetes drug …

Bristol-Myers gets approval for its diabetes drug Saxagliptin [Onglyza] in the European Union (EU) Read more »

Tagged with: , , ,